Magnetic resonance spectroscopy in clinical oncology

Onkologie

Volumn 27, Issue 3, 2004, Pages 304-309

  Golder, W ^a  

^a DRK KLINIKEN BERLIN WESTEND   (Germany)

Author keywords

5 Fluorouracil; Magnetic resonance spectroscopy; Neurotoxicity; Tumor metabolism

Indexed keywords

FLUOROURACIL; PROTON; TUMOR MARKER;

ARTICLE; BIOAVAILABILITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HEALTH CARE PLANNING; HUMAN; IN VIVO STUDY; MEDICAL INFORMATION; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHATE BLOOD LEVEL; REDUCTION; TREATMENT OUTCOME; TUMOR VOLUME; METABOLISM; METHODOLOGY; NEOPLASM; ONCOLOGY; REVIEW;

HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MEDICAL ONCOLOGY; NEOPLASMS; PROTONS; TUMOR MARKERS, BIOLOGICAL;

EID: 3943052746     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077983     Document Type: Article

References (37)

1. Zakian KL, Koutcher JA, Ballon D, Hricak H, Ling CC: Developments in nuclear magnetic resonance imaging and spectroscopy: Applications to radiation oncology. Semin Radiat Oncol 2001;11:3-15.
2. Barker PB, Hearshen DO, Boska MD: Single-voxel proton MRS of the human brain at 1.5 T and 3.0 T. Magn Reson Med 2001;45:765-769.
3. Bartha R, Drost DJ, Menon RS, Williamson PC: Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med 2000;44:185-192.
4. Bottomley PA: The rise of human in vivo NMR spectroscopy. Solid State Nucl Magn Reson 1997;9:29-40.
5. Constantinidis I: MRS methodology. Adv Neurol 2000;83:235-246.
6. Stubbs M, Veech RL, Griffiths JR: Tumor metabolism: The lessons of magnetic resonance spectroscopy. Adv Enzyme Regul 1995;35:101-115.
7. Leclerc X, Huisman TA, Sorensen AG: The potential of proton magnetic resonance spectroscopy ((1)H-MRS) in the diagnosis and managament of patients with brain tumours. Curr Opin Oncol 2002;14:292-298.
8. Golder W: Wandel und Perspektiven der diagnostischen Onkoradiologie. Onkologie 2002;25(Suppl 1):48-53.
9. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotsis ED, Heerschap A, Kamada K, Lee BCP, Mengeot MM, Moser E, Padavic-Shaller KA, Sanders JA, Spraggins TA, Stillman AE, Terwey B, Vogl TJ, Wicklow K, Zimmermann RA: Proton magnetic resonance spectroscopy in patients with glial tumours: A multicenter study. J Neurosurg 1996;84:449-458.
10. Kaminogo M, Ishimaru H, Morikawa M, Ochi M, Ushijima R, Tani M, Matsuo Y, Kawakubo J, Shibata S: Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 2001;43:353-363.
11. Ishimaru H, Morikawa M, Iwanaga S, Kaminogo M, Ochi M, Hayashi K: Differentiation between high-grade glioma and metastatic brain tumour using single-voxel proton MR spectroscopy. Eur Radiol 2001;11:1784-1791.
12. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK: Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593-1603.
13. Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM: Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000;18:1020-1026.
14. Prost RW, Mark LP, Rand SD, Kim TA, Haughton VM: Recent advances in MR spectroscopy expand its applications in neurologic disease. WMJ 1997;96:41-45.
15. Merchant TE, Kasimos JN, Vroom T, de Bree E, Iwata JL, de Graaf PW, Glonek T: Malignant breast tumor phospholipid profiles using (31)P magnetic resonance. Cancer Lett 2002;176:159-167.
16. Allen JR, Prost RW, Griffith OW, Erickson SJ, Erickson BA: In vivo proton (H1) magnetic resonance spectroscopy for cervical carcinoma. Am J Clin Oncol 2001;24:522-529.
17. Garcia-Segura JM, Sanchez-Chapado M, Ibarburen C, Viano J, Angulo JC, Gonzalez J, Rodriguez-Vallejo JM: In vivo proton resonance spectroscopy of diseased prostate: Spectroscopic features of malignant versus benign pathology. Magn Reson Imaging 1999;17:755-765.
18. Negendank WG: MR spectroscopy of musculoskeletal soft-tissue tumors. Magn Reson Imaging Clin N Am 1995;3:713-725.
19. Sostman HD, Prescott DM, Dewhirst MW, Dodge RK, Thrall DE, Page RL, Tucker JA, Harrelson JM, Reece G, Leopold KA: MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas. Radiology 1994;190:269-275.
20. Prescott DM, Charles HC, Sostman HD, Dodge RK, Thrall DE, Page RL, Tucker JA, Harrelson LM, Leopold KA, Oleson JR: Therapy monitoring in human and canine soft tissue sarcomas using magnetic resonance imaging and spectroscopy. Int J Radiat Oncol Biol Phys 1994;28:415-423.
21. Walecki J, Sokol M, Pieniazek P, Maciejewski B, Tarnawski R, Krupska T, Wydmanski J, Brzezinski J, Grieb P: Role of short TE 1H-MR spectroscopy in monitoring of postoperation irradiated patients. Eur J Radiol 1999;30:154-161.
22. Tarnawski R, Sokol M, Pieniazek P, Maciejewski B, Walecki J, Miszczyk L, Krupska T: 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys 2002;52:1271-1276.
23. Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G: Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol 2001;22:1316-1324.
24. Usenius T, Usenius JP, Tenhunen M, Vainio P, Johannson R, Soimakallio S, Kauppinen R: Radiation-induced changes in human brain metabolites as studied by 1H nuclear magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 1995;33:719-724.
25. Movsas B, Li BS, Babb JS, Fowble BL, Nicolaou N, Gonen O: Quantifying radiation therapy-induced brain injury with whole-brain proton MR spectroscopy: Initial observations. Radiology 2001;221:327-331.
26. Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, Nelson SJ, Verhey LJ, Larson DA: MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001;50:915-928.
27. Kristjansen PE, Pedersen EJ, Quistorff B, Elling F, Spang-Thomsen M: Early effects of radiotherapy in small cell lung cancer xenografts monitored by 31P magnetic resonance spectroscopy and biochemical analysis. Cancer Res 1990;50:4880-4884.
28. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, Jacobs SC, Naslund MJ, Sklar GN, Alexan der RB, Yu C: Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002;52:429-438.
29. Zelefsky MJ, Cohen G, Zakian KL, Dyke J, Koutcher JA, Hricak H, Schwartz L, Zaider M: Intraoperative conformal optimisation for transperineal prostate implantation using magnetic resonance spectroscopic imaging. Cancer J 2000;6:249-255.
30. Hanusovska E, Dovinova I, Tkac I, Novotyn L: Application of NMR spectroscopy in biochemical studies of tumor cells sensitive and resistant to anticancer drugs. Neoplasma 1998;45:187-197.
31. Davidson A, Tait DM, Payne GS, Hopewell JW, Leach MO, Watson M, MacVicar AD, Britton JA; Ashley S: Magnetic resonance spectroscopy in the evaluation of neurotoxicity following cranial irradiation for childhood cancer. Br J Radiol 2000;73:421-424.
32. Glaholm J, Leach MO, Collins D, al Jehazi B, Sharp JC, Smith TA, Adach J, Hind A, McCready VR, White H: Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy. Br J Radiol 1990;63:547-553.
33. Findlay MP, Leach MO, Cunningham D, Collins DJ, Payne GS, Glaholm J, Mansi JL, McCready VR: The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferonalpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study. Ann Oncol 1993;4:597-602.
34. Schlemmer HP, Becker M, Bachert P, Dietz A, Rudat V, Vanselow B, Wollensack P, Zuna I, Knopp MV, Weidauer H, Wannenmacher M, van Kaick G: Alterations of intratumoural pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res 1999;59:2363-2369.
35. Kettelhack C, Wickede M, Vogl T, Schneider U, Hohenberger P: 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer 2002;94:1557-1564.
36. Sijens PE, Eggermont AM, van Dijk PV, Oudkerk M: 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed 1995;8:215-224.
37. Bottomley PA: Spatial localization in NMR-spectroscopy in vivo. Ann NY Acad Sci 1987;508:333-348.